| Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family | Sarah de Crescenzo | 01/27/20 | Boston |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie | Frank Vinluan | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval | Frank Vinluan | 01/23/20 | Boston |
| After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune | Mike Ward | 01/23/20 | National |
| FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs | Frank Vinluan | 01/22/20 | Boston |
| Horizon Gets Early FDA OK for First Thyroid Eye Disease Treatment | Sarah de Crescenzo | 01/22/20 | National |
| Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits | Frank Vinluan | 01/22/20 | New York |
| CEOs of Women’s Health Companies Fight to Open Investment Floodgates | Sarah de Crescenzo | 01/22/20 | San Diego |
| After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020 | Sarah de Crescenzo | 01/21/20 | San Diego |
| Of Science and Sea Urchins: Researchers Plumb Oceans for Biological Insights | Melissa Fassbender | 01/21/20 | Boston |
| Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers | Frank Vinluan | 01/17/20 | San Francisco |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal | Frank Vinluan | 01/16/20 | Boston |
| Event Announcement: Xcelerating Life Sciences San Diego | Editors | 01/16/20 | National |
| Mayo Clinic Joins $60M Financing for Biomedical Software Firm nference | Melissa Fassbender | 01/16/20 | Boston |
| Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D | Frank Vinluan | 01/15/20 | New York |
| Phage Therapy Firm APT Lands DoD Contract for Antibiotic Alternative | Melissa Fassbender | 01/15/20 | National |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery | Melissa Fassbender | 01/14/20 | National |
| Schrödinger Sets Course for IPO to Support Growing Internal Pipeline | Frank Vinluan | 01/14/20 | New York |
| Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive | Sarah de Crescenzo | 01/14/20 | San Diego |
| NeoGenomics Nabs Human Longevity’s Oncology Division for $37M | Melissa Fassbender | 01/13/20 | National |
| Biogen Adds Another Neuro Drug to Pipeline in Deal With Pfizer | Melissa Fassbender | 01/13/20 | Boston |
| Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug | Frank Vinluan | 01/13/20 | National |
| Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans | Frank Vinluan | 01/13/20 | Boston |
| Roche Pays $40M to Use Amunix Pharma’s Half-Life Extension Tech | Melissa Fassbender | 01/13/20 | National |
| Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial | Sarah de Crescenzo | 01/13/20 | San Francisco |
| Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsia | Sarah de Crescenzo | 01/11/20 | San Diego |
